---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-030048"
form_type: "8-K"
ticker: "SMNR"
cik: "0001913577"
company_name: "Semnur Pharmaceuticals, Inc."
filed_at: "2025-04-09T23:59:59+00:00"
generated_at: "2026-05-23T18:36:40.975822+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Denali Capital receives Nasdaq delisting determination; must appeal by April 9 or face suspension

## Summary
- On April 2, 2025, Nasdaq staff determined Denali failed to meet MVLS, total assets, and public float rules.
- Company must appeal by April 9, 2025 to avoid delisting; if no appeal, trading suspended April 11, 2025.
- Company expects to trade on OTC market after delisting; plans to remain a reporting company.
- Delisting not expected to immediately impact planned business combination with Semnur Pharmaceuticals.

## SEC filing metadata
- accession: 0001213900-25-030048
- form_type: 8-K
- ticker: SMNR
- cik: 0001913577
- company_name: Semnur Pharmaceuticals, Inc.
- filed_at: 2025-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1913577/000121390025030048/0001213900-25-030048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1913577/000121390025030048/ea0237665-8k425_denali.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-030048
- JSON: https://secwatch.observer/filing/0001213900-25-030048.json
- Plain text: https://secwatch.observer/filing/0001213900-25-030048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.